E-LIB Suche - Ergebnisse für: Bril V

1

P.053 Concomitant corticosteroid use in ravulizumab-treated..:

Nicolle, MW ; Annane, D ; Meisel, A...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51 (2024) s1 - p. S30-S30 , 2024

Link: https://doi.org/10.1017/..

2

P.057 Achievement of minimal symptom expression in acetylch..:

Bril, V ; Muppidi, S ; Howard Jr., JF...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51 (2024) s1 - p. S31-S31 , 2024

Link: https://doi.org/10.1017/..

3

P275 Response to rozanolixizumab in patients with generaliz..:

Vissing, J. ; Drużdż, A. ; Grosskreutz, J....
Neuromuscular Disorders. 33 (2023) - p. S178-S179 , 2023

Link: https://doi.org/10.1016/..

4

P.034 Minimal symptom expression following treatment with e..:

Siddiqi, Z ; Howard Jr, JF ; Bril, V...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S67-S67 , 2023

Link: https://doi.org/10.1017/..

5

P.044 Efficacy, safety, and tolerability of efgartigimod in..:

Bril, V ; Vu, T ; Karam, C...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S70-S70 , 2023

Link: https://doi.org/10.1017/..

6

P.045 Safety profile overview of Efgartigimod Clinical Tria..:

Bril, V ; Behin, A ; Gwathmey, K...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S70-S70 , 2023

Link: https://doi.org/10.1017/..

7

P.043 Long-term safety, tolerability, and efficacy of efgar..:

Genge, A ; Pasnoor, M ; Bril, V...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S69-S69 , 2023

Link: https://doi.org/10.1017/..

8

P277 Long-term safety, tolerability, and efficacy of Efgart..:

Ashcraft, E. ; Bril, V. ; Pasnoor, M....
Neuromuscular Disorders. 33 (2023) - p. S179 , 2023

Link: https://doi.org/10.1016/..

9

A cross-sectional study of gender differences in quality of..:

Hamoy-Jimenez, G. ; Elahmar, H. A. ; Mendoza, M....
Orphanet Journal of Rare Diseases. 17 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

10

Prospects to create and apply artificial intelligence in th..:

Kadyrova, G M ; Shedko, Y N ; Orlanyuk-Malitskaya, L A.
IOP Conference Series: Earth and Environmental Science. 650 (2021) 1 - p. 012014 , 2021

Link: https://doi.org/10.1088/..

11

20. Practical application of subcutaneous immunoglobulin fo..:

Schaik van, I.N. ; Bril, V. ; Geloven van, N....
Clinical Neurophysiology. 131 (2020) 3 - p. e9 , 2020

Link: https://doi.org/10.1016/..

12

Comparison of the single simple question and the patient ac..:

Menon, D. ; Barnett, C. ; Bril, V.
European Journal of Neurology. 27 (2020) 11 - p. 2286-2291 , 2020

Link: https://doi.org/10.1111/..

13

Chronic immunoglobulin maintenance therapy in myasthenia gr..:

Alcantara, M. ; Sarpong, E. ; Barnett, C...
European Journal of Neurology. 28 (2020) 2 - p. 639-646 , 2020

Link: https://doi.org/10.1111/..

14

Subcutaneous immunoglobulin (SCIG) for maintenance treatmen..:

Cocito, D. ; Peci, E. ; Lauria Pinter, G....
Clinical Neurophysiology. 130 (2019) 1 - p. e10 , 2019

Link: https://doi.org/10.1016/..

15

Chronic stress, depression and personality type in patients..:

Bogdan, A. ; Barnett, C. ; Ali, A....
European Journal of Neurology. 27 (2019) 1 - p. 204-209 , 2019

Link: https://doi.org/10.1111/..